A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Etrasimod (Primary)
- Indications Eosinophilic oesophagitis
- Focus Therapeutic Use
- Acronyms VOYAGE
- Sponsors Arena Pharmaceuticals; Pfizer
Most Recent Events
- 04 Sep 2023 Last checked against European Clinical Trials Database record.
- 21 Jul 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2022 Planned End Date changed from 1 Jun 2023 to 4 Jul 2023.